Followers | 18 |
Posts | 899 |
Boards Moderated | 0 |
Alias Born | 11/19/2010 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, March 19, 2014 11:16:15 AM
I believe with positive news on the phase 3 Myocell trials, we'll surpass 0.10 . Factor in further positive 12-month results from the phase 1 Angel trial, mixed with actual revenue from both recent partnerships and international training programs, I would expect to see higher.
Financials showing enough revenue to have cleared off debt, cover all expenses including trial expenses, and maybe a little left for profit, I would expect 0.50+.
The FDA is only for the American market. That would be huge because it proves without a shadow of a doubt the effectiveness of BioHeart's product.
But the medical tourism sector is HUGE.
With the recent partnerships, international revenue could be quite significant, considering the $BILLIONS that are already spent on treatments, and that BioHeart's treatments are proving to be far more effective.
This wasn't always a "penny stock" and I'm confident enough to say I'll ride this into BHRT being worth a few dollars per share again. We're not far off from key mile stones, and we seem to be accomplishing goals and then some at an aggressive and impressive pace.
My honest opinions.
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM